ALECHealthcare · BiotechnologyThe 7 Wall Street analysts covering Alector, Inc. hold a median 12-month price target of $3 — +33.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Alector, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (78): Analysts have, on balance, been raising their forecasts.
Quality (31): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ALEC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +33.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $8.00 |
| 14 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $8.00 |
| 6 Oct 2026 | Morgan Stanley | Maintains | Underweight | $2.00 → $3.00 |
| 6 Oct 2026 | Morgan Stanley | Maintains | Underweight | — |
| 15 Apr 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 15 Apr 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 10 Mar 2026 | BTIG | Upgrade | Buy | — |
| 22 Oct 2025 | BTIG | Downgrade | Neutral | — |
| 22 Oct 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 22 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Oct 2025 | TD Cowen | Downgrade | Hold | — |
| 22 Oct 2025 | William Blair | Downgrade | Market Perform | — |
| 25 Sept 2025 | BTIG | Reiterates | Buy | — |
| 28 July 2025 | Mizuho | Upgrade | Outperform | — |
| 9 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Mar 2025 | Morgan Stanley | Assumes | Underweight | $3.00 → $1.50 |
| 27 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Dec 2024 | Stifel | Downgrade | Hold | — |
| 26 Nov 2024 | BTIG | Maintains | Buy | — |
| 26 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ALEC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Alector, Inc. returned +44.5% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 10% of US stocks
Cheaper than 98% of US stocks
Cheaper than 68% of US stocks
Higher than 4% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alector, Inc. has a market value of $234.5M and an enterprise value of $94.4M.
Revenue in the twelve months to 30 June 2026: $13.9M. The latest quarter shrank 57.8% year on year.
Net income over the same four quarters: −$117.9M, a −850.1% net margin.
Diluted earnings per share, trailing twelve months: $−1.10.
Free cash flow in the twelve months to 30 June 2026: −$158.4M.
Trailing P/E: −1.5×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alector, Inc. employs 103 people — $135K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alector, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says Alector lacks the combination of two key factors it associates with a likely earnings beat ahead of the company’s upcoming report. The headline frames the item around whether Alector will report negative third-quarter earnings.
Why it matters — Alector watchers may note Zacks’ expectations-focused assessment ahead of the Q3 earnings report.
Alector priced an underwritten offering of 36.6 million common shares at $2.05 per share, with gross proceeds expected to be $75.03 million before discounts, commissions, and other estimated expenses. The offering is expected to close on or about October 19, 2026, subject to customary conditions.
Why it matters — The offering adds a substantial share issuance and expected proceeds to Alector’s capital picture, while the stated closing remains subject to customary conditions.
Seeking Alpha published a transcript titled “Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments.” The provided excerpt contains only the headline and no details from the discussion.
Why it matters — The item concerns Alector’s neurodegeneration therapies and pipeline, but the excerpt provides no specific developments for investors to assess.
Alector outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases. The pipeline includes an anti-amyloid beta antibody for Alzheimer's disease and two siRNA programs targeting tau and alpha-synuclein.
Why it matters — The strategy provides ALEC watchers with an update on the company's research programs for Alzheimer's and Parkinson's-related disease targets.
Alector will host a virtual research and development event highlighting its wholly owned Alector Brain Carrier-enabled pipeline. The agenda will feature progress on AL137, AL164, and AL062.
Why it matters — The event will provide ALEC watchers with updates on three programs spanning anti-amyloid beta, tau siRNA, and alpha-synuclein siRNA approaches.
The 7 Wall Street analysts covering Alector, Inc. have a median 12-month price target of $3, with estimates ranging from $1 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Alector, Inc., 3 rate it a Buy, 2 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Alector, Inc. 55 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Alector, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +33.9% from the last close, and Ticker Nerd's factor model ranks Alector, Inc. 55 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alector, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALEC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $8 over the next 12 months.
Alector, Inc. returned +44.5% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know". Zacks says Alector lacks the combination of two key factors it associates with a likely earnings beat ahead of the company’s upcoming report. The headline frames the item around whether Alector will report negative third-quarter earnings.
Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. Alector Inc. applies its immuno-neurology platform to target the immune dysfunction and protein-related pathology associated with conditions such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia. The company’s current portfolio includes monoclonal antibody and other biologic programs designed to restore healthy immune function in the brain, supported by biomarker-guided clinical development. It also advances Alector Brain Carrier, a proprietary blood-brain barrier platform intended to improve therapeutic delivery to the central nervous system. Headquartered in South San Francisco, California, Alector Inc. operates as a research-driven biopharmaceutical company with a focus on translating genetics, immunology, and neuroscience into treatments for severe brain disorders.
CEO Dr. Arnon Rosenthal Ph.D. · 103 employees · United States · https://www.alector.com
